P. D. Stein, A. Beemath, and R. E. Olson, Obesity as a risk factor in venous thromboembolism, Am. J. Med, vol.118, pp.978-980, 2005.

A. T. Rocha, A. G. De-vasconcellos, E. R. Da-luz, D. M. Neto, E. S. Araújo et al., Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery, Obes. Surg, vol.16, pp.1645-1655, 2006.

M. H. Jamal, R. Corcelles, H. Shimizu, M. Kroh, F. M. Safdie et al., Thromboembolic events in bariatric surgery: a large multi-institutional referral center experience, Surg. Endosc, vol.29, pp.376-380, 2015.

J. A. Sapala, M. H. Wood, M. P. Schuhknecht, and M. A. Sapala, Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis, Obes. Surg, vol.13, pp.819-825, 2003.

B. J. Carmody, H. J. Sugerman, J. M. Kellum, M. K. Jamal, J. M. Johnson et al., Pulmonary embolism complicating bariatric surgery: detailed analysis of a single institution's 24-year experience, J. Am. Coll. Surg, vol.203, pp.831-837, 2006.

P. D. Stein and F. Matta, Pulmonary embolism and deep venous thrombosis following bariatric surgery, Obes. Surg, vol.23, pp.663-668, 2013.

M. J. Hanley, D. R. Abernethy, and D. J. Greenblatt, Effect of obesity on the pharmacokinetics of drugs in humans, Clin. Pharmacokinet, vol.49, pp.71-87, 2010.

A. J. Mayr, M. Dünser, S. Jochberger, D. Fries, A. Klingler et al., Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin, Thromb. Res, vol.105, pp.201-204, 2002.

S. G. Frederiksen, J. L. Hedenbro, and L. Norgren, Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients, Br. J. Surg, vol.90, pp.547-548, 2003.

A. L. Freeman, R. C. Pendleton, and M. T. Rondina, Prevention of venous thromboembolism in obesity, Expert Rev. Cardiovasc. Ther, vol.8, pp.1711-1721, 2010.

B. O. Rowan, D. A. Kuhl, M. D. Lee, D. S. Tichansky, and A. K. Madan, Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin, Obes. Surg, vol.18, pp.162-166, 2008.

E. P. Simone, A. K. Madan, D. S. Tichansky, D. A. Kuhl, and M. D. Lee, Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery, Surg. Endosc, vol.22, pp.2392-2395, 2008.

M. J. Borkgren-okonek, R. W. Hart, J. E. Pantano, P. C. Rantis, P. J. Guske et al., Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity, Surg. Obes. Relat. Dis, vol.4, pp.625-631, 2008.

D. Imberti, C. Legnani, E. Baldini, M. Cini, A. Nicolini et al., Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study), Thromb. Res, vol.124, pp.667-671, 2009.

F. Celik, A. D. Huitema, J. H. Hooijberg, A. W. Van-de-laar, D. P. Brandjes et al., Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels, Obes. Surg, vol.25, pp.628-634, 2015.

M. A. Bartlett, K. F. Mauck, and P. R. Daniels, Prevention of venous thromboembolism in patients undergoing bariatric surgery, Vasc. Health Risk Manag, vol.11, pp.461-477, 2015.

J. I. Mechanick, A. Youdim, D. B. Jones, W. T. Garvey, D. L. Hurley et al., Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: cosponsored by, Obesity, vol.21, pp.1-27, 2013.

, American Society for Metabolic Bariatric Surgery Clinical Issues Committee, ASMBS updated position statement on prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients, Surg. Obes. Relat. Dis, vol.9, pp.493-497, 2013.

M. K. Gould, D. A. Garcia, S. M. Wren, P. J. Karanicolas, J. I. Arcelus et al., Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, Chest, vol.141, pp.227-277, 2012.

M. T. Rondina, M. Wheeler, G. M. Rodgers, L. Draper, and R. C. Pendleton, Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients, Thromb. Res, vol.125, pp.220-223, 2010.

K. Singh, E. R. Podolsky, S. Um, S. Saba, I. Saeed et al., Evaluating the safety and efficacy of BMI-based preoperative administration of low-molecular-weight heparin in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery, Obes. Surg, vol.22, pp.47-51, 2012.

C. Samama, B. Gafsou, T. Jeandel, S. Laporte, A. Steib et al., French society of anaesthesia and intensive care. Guidelines on perioperative venous thromboembolism prophylaxis. Update, Ann. Fr. Anesth. Reanim, vol.30, pp.947-951, 2011.

A. M. Gotto, E. L. Bierman, W. E. Connor, C. H. Ford, I. D. Frantz et al., Recommendations for treatment of hyperlipidemia in adults: a joint statement of the Nutrition Committee and the Council on Arteriocslerosis, Circulation, vol.69, pp.1065-1090, 1984.

S. Janmahasatian, S. B. Duffull, S. Ash, L. C. Ward, N. M. Byrne et al., Quantification of lean bodyweight, Clin. Pharmacokinet, vol.44, pp.1051-1065, 2005.

M. P. Pai and F. P. Paloucek, The origin of the ideal body weight equations, Ann. Pharmacother, vol.34, pp.1066-1069, 2000.

M. Y. Wei and S. M. Ward, The anti-factor xa range for low molecular weight heparin thromboprophylaxis, Hematol. Rep, vol.7, p.5844, 2015.

S. Schulman, U. Angerås, D. Bergqvist, B. Eriksson, M. R. Lassen et al., Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients, J. Thromb. Haemost. JTH, vol.8, pp.202-204, 2010.

L. Angrisani, A. Santonicola, P. Iovino, G. Formisano, H. Buchwald et al., Bariatric surgery worldwide 2013, vol.25, pp.1822-1832, 2015.

J. Thereaux, T. Lesuffleur, S. Czernichow, A. Basdevant, S. Msika et al., To what extent does posthospital discharge chemoprophylaxis prevent venous thromboembolism after bariatric surgery?: Results from a nationwide cohort of more than 110,000 patients, Ann. Surg, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01761872

S. G. Parker, E. R. Mcglone, W. R. Knight, P. Sufi, and O. A. Khan, Enoxaparin venous thromboembolism prophylaxis in bariatric surgery: a best evidence topic, Int. J. Surg. Lond. Engl, vol.23, pp.52-56, 2015.

R. Ikesaka, A. Delluc, G. L. Gal, and M. Carrier, Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis, Thromb. Res, vol.133, pp.682-687, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01026433

B. Dufour, M. Toussaint-hacquard, A. Kearney-schwartz, M. D. Manckoundia, M. C. Laurain et al., Glomerular filtration rate estimated by Cockcroft-Gault formula better predicts anti-Xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin, J. Nutr. Health Aging, vol.16, pp.647-652, 2012.

B. Green and S. B. Duffull, What is the best size descriptor to use for pharmacokinetic studies in the obese?, Br. J. Clin. Pharmacol, vol.58, pp.119-133, 2004.

J. H. Friesen, Lean-scaled weight: a proposed weight scalar to calculate drug doses for obese patients, Can. J. Anaesth, vol.60, pp.214-215, 2013.

J. Diepstraten, C. M. Hackeng, S. Van-kralingen, J. Zapletal, E. P. Van-dongen et al., Anti-Xa levels 4 h after subcutaneous administration of 5,700 IU nadroparin strongly correlate with lean body weight in morbidly obese patients, Obes. Surg, 2012.

J. Diepstraten, E. J. Janssen, C. M. Hackeng, E. P. Van-dongen, R. J. Wiezer et al., Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint, Eur. J. Clin. Pharmacol, vol.71, pp.25-34, 2015.

G. Egan and M. H. Ensom, Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review, Can. J. Hosp. Pharm, vol.68, pp.33-47, 2015.